相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Editorial Material
Medicine, General & Internal
[Anonymous]
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE
(2023)
Letter
Medicine, General & Internal
Sophie Caillard et al.
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Hematology
Moshe Mittelman et al.
Summary: Limited evidence suggests that COVID-19 vaccines may be less effective in patients with impaired immunity. A study on patients with hematological neoplasms showed that vaccinated patients had a higher risk of COVID-19 infection, hospitalization, and death compared to vaccinated controls. Patients receiving treatment had an even higher risk. Ways to enhance COVID-19 immunity in this patient population should be explored.
Article
Biochemistry & Molecular Biology
Paul R. Wratil et al.
Summary: This study reports on the dynamics of neutralizing antibodies in individuals convalescing from coronavirus disease 2019 or who are vaccine-naive and subsequently vaccinated. The findings suggest that infection-plus-vaccination-induced hybrid immunity or triple immunization can induce high-quality antibodies with superior neutralization capacity against variants of concern, including omicron.
Article
Immunology
Jan-Stephan F. Sanders et al.
Summary: In kidney patients, the immunogenicity, tolerability, and safety of COVID-19 vaccination vary. Kidney transplant recipients have a poor immune response, while patients with CKD G4/5 and those on dialysis have a comparable response to the control group. Dialysis patients and transplant recipients experience fewer adverse events after vaccination.
Article
Hematology
Sabine Haggenburg et al.
Summary: Vaccination guidelines for hematological patients are typically conservative. However, this study shows that most patients, even those with compromised immune systems, can develop sufficient antibody concentrations after receiving the Moderna vaccine. However, certain treatments may affect the vaccine's efficacy.
Review
Oncology
Annika Fendler et al.
Summary: The efficacy and immunogenicity of COVID-19 vaccines in cancer patients are uncertain due to their exclusion from pivotal clinical trials. In this Review, the current knowledge on vaccine efficacy and immune responses in cancer patients is summarized, highlighting key factors that may affect vaccine efficacy in this population.
NATURE REVIEWS CLINICAL ONCOLOGY
(2022)
Article
Immunology
Yuezhou Chen et al.
Summary: Key features of immune memory include stronger and faster antigen-specific antibody responses to repeat infection. Understanding the recognition of viral variants by memory cells and the influence of immune recall on the longevity of antibody responses is crucial. A study analyzing the recognition of SARS-CoV-2 variants, dynamics of memory B cells, and secreted antibodies over time after infection, vaccination, and boosting found that a two-dose vaccination regimen after natural infection resulted in greater antibody stability and broader recognition of variants. In COVID-naive individuals, a third mRNA vaccine dose conferred cross-variant neutralization potency and stability similar to hybrid immunity from infection and vaccination. Recovered individuals with enhanced antibody stability harbored more memory B cells cross-reactive to endemic coronaviruses early after infection. These findings highlight the impact of SARS-CoV-2 antigen challenges on antibody responses and repertoire composition.
SCIENCE IMMUNOLOGY
(2022)
Article
Hematology
Sabine Haggenburg et al.
Summary: Patients with hematologic conditions are at higher risk of severe COVID-19 and COVID-19-related death due to immune deficiencies. Three doses of COVID-19 vaccination can lead to antibody levels comparable to healthy adults in most patients. B-cell depleted patients may have poor humoral responses, but vaccination can induce strong cellular immune responses. Population-based vaccine effectiveness studies are needed to confirm the effectiveness of three-dose vaccination schedules and COVID-19 booster vaccinations in protecting patients with hematologic malignancies against severe COVID-19 and COVID-19-related death.
SEMINARS IN HEMATOLOGY
(2022)
Article
Oncology
Lennard Y. W. Lee et al.
Summary: Third dose vaccine boosters are effective for most cancer patients, but their effectiveness is lower for lymphoma patients. Even after receiving three doses of the vaccine, many cancer patients still face the risk of coronavirus infection. Breakthrough infections may disrupt cancer care and treatment, with potentially adverse consequences on survival outcomes. The data support further pharmacological intervention to limit the disruption of cancer care by the coronavirus.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Lucy B. Cook et al.
Summary: SARS-CoV-2 infection and COVID-19 have high mortality among patients with haematological malignancies. Although global vaccine rollouts have reduced hospitalizations and deaths, the efficacy of vaccines in these patients is reduced. A retrospective study on 381 patients with haematological malignancies shows that a third vaccine dose enhances SARS-CoV-2 antibody responses.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Noppacharn Uaprasert et al.
Summary: Patients with hematologic malignancies, especially those with lymphoid malignancies and/or receiving CART, B-cell targeted therapies, or JAK inhibitors, showed poor seroconversion rates after SARS-CoV-2 vaccination. A minority of patients achieved seroconversion after booster doses. Further strategies to enhance immune response in these patients are necessary.
BLOOD CANCER JOURNAL
(2022)
Letter
Hematology
Lara S. Boerenkamp et al.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Oncology
Sabine Haggenburg et al.
Summary: This study aimed to assess the effectiveness of a third mRNA-1273 vaccination in immunocompromised patients with hematologic cancers. The results showed that a third vaccination had a significant effect in patients with recovering immune systems, but yielded poorer results in certain specific patient groups. Therefore, the administration of a third dose of vaccine should be considered in patients with hematologic cancers and evaluated on an individual basis.
Article
Oncology
Sean H. Lim et al.
Summary: Patients with hematological malignancies, especially those undergoing active anticancer treatment or on anti-CD20 therapy, show compromised immune responses to COVID-19 vaccination. However, booster vaccination can significantly improve antibody responses in indolent B-cell lymphoma patients, and antigen-specific T-cell responses are observed in the majority of patients after a third dose, regardless of their cancer treatment status.
Article
Oncology
Sabine Haggenburg et al.
Summary: This study found that a third dose of mRNA-1273 vaccine can increase neutralizing antibody concentrations in immunocompromised patients with hematologic cancers, especially in those with recovering immune systems.
Article
Oncology
Sjoukje F. Oosting et al.
Summary: This study aimed to evaluate the immunogenicity and safety of the mRNA-1273 COVID-19 vaccine for patients with solid tumours receiving systemic cancer treatment. The majority of patients developed an adequate antibody response after two vaccinations, indicating the vaccine is safe in these patients. Some patients with an inadequate response may benefit from a third vaccination.
Article
Hematology
Yair Herishanu et al.
Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.
Article
Public, Environmental & Occupational Health
Peter J. Embi et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Biochemistry & Molecular Biology
Erin M. Bange et al.
Summary: In patients with cancer and COVID-19, those with hematologic cancer show impaired immune responses compared to solid cancer patients. CD8 T cells play a crucial role in survival, even in the presence of limited humoral responses. The presence of SARS-CoV-2-specific T cell responses in hematologic cancer patients suggests a potential therapeutic target.
Article
Oncology
Evangelos Terpos et al.
Summary: Recent data shows suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Specifically, patients with multiple myeloma (MM) exhibit lower production of neutralizing antibodies (NAbs) after vaccination compared to healthy controls, especially when undergoing treatment with anti-CD38 or belamaf. Timely vaccination, possibly during treatment-free periods, is emphasized for this group of patients.
BLOOD CANCER JOURNAL
(2021)
Article
Medicine, General & Internal
Julia Hippisley-Cox et al.
Summary: This study derived and validated risk prediction algorithms to estimate the risk of covid-19 related mortality and hospital admission in UK adults after one or two doses of covid-19 vaccination. The study found that the risk of covid-19 mortality and hospital admission was associated with age, sex, ethnic origin, deprivation, body mass index, a range of comorbidities, and SARS-CoV-2 infection rate. Various conditions, such as Down's syndrome, kidney transplantation, sickle cell disease, and certain other diseases, were identified as having higher risk of covid-19 mortality.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Hematology
Kazimieras Maneikis et al.
Summary: Patients with haematological malignancies exhibit blunted and heterogeneous antibody responses after receiving the full course of BNT162b2 mRNA vaccination. Those actively treated with BTKIs, ruxolitinib, venetoclax, or anti-CD20 antibody therapies show the poorest responses, while patients who received tyrosine kinase inhibitors or various types of stem-cell transplantation had higher antibody responses. Severe breakthrough SARS-CoV-2 infections and deaths in fully vaccinated patients with haematological malignancies highlight the importance of continued adherence to non-pharmacological interventions and household vaccination.
LANCET HAEMATOLOGY
(2021)
Article
Multidisciplinary Sciences
Tom G. Caniels et al.
Summary: New SARS-CoV-2 variants pose a threat to human immunity, with most individuals showing significantly reduced neutralization against three variants, especially B.1.351. Hospitalized patients and vaccine recipients maintained sufficient neutralizing titers, while a substantial portion of non-hospitalized patients exhibited no neutralization against B.1.351.
Article
Oncology
Annika Fendler et al.
Summary: A cohort study evaluated 585 cancer patients following vaccination with BNT162b2 or AZD1222 vaccines, finding lower antibody responses in patients with hematological malignancies compared to those with solid tumors. Patients with hematological malignancies also had reduced neutralizing antibody responses compared to individuals without cancer. The study highlights the importance of managing cancer patients during the ongoing COVID-19 pandemic.
Review
Immunology
Debbie Van Baarle et al.
